Action GLENMARK GLENMARK PHARMACEUTICALS LIMITED
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Glenmark Pharmaceuticals Limited

Actions

GLENMARK

INE935A01035

Marché Fermé - NSE India S.E.
Autres places de cotation
 13:58:32 07/06/2024 		Varia. 5j. Varia. 1 janv.
1 194 INR -1,30 % Graphique intraday de Glenmark Pharmaceuticals Limited +2,91 % +39,84 %
30/05 Transcript : Glenmark Pharmaceuticals Limited - Analyst/Investor Day
29/05 Assertio Therapeutics nomme Brendan O'Grady au poste de directeur general MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Glenmark Pharmaceuticals : Investor Day 2024
Glenmark Pharmaceuticals : Investors Day 2024
Assertio Therapeutics Names Brendan O'Grady as Chief Executive
Glenmark Pharmaceuticals : Q4FY 2023-24
INDIA STOCKS-Metal stocks lead Indian shares higher
Glenmark Pharmaceuticals Widens Consolidated Net Loss in Fiscal Q4
Glenmark Pharmaceuticals : Q4 FY 2023-24
INDIA STOCKS-Indian shares at record highs, boosted by pharma stocks, Adani Ports
Glenmark Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2025
Glenmark Pharmaceuticals : Pharma Reports Q4 FY2023-24 Financial results
Glenmark Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024
Glenmark Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024
Glenmark Pharmaceuticals Limited Recommends Dividend for the Financial Year 2023-24
India's Sensex Ends Down, Nifty Up Ahead of National Poll Outcome
Glenmark Pharma Arm to Market Two Beigene Cancer Drugs in India
Glenmark Pharmaceuticals receives ANDA approval for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%|0.5%
Glenmark Pharmaceuticals Receives ANDA Approval for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%|0.5%
Glenmark Pharmaceuticals : receives ANDA approval for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%|0.5%
Glenmark Pharmaceuticals to Acquire 26% Stake in Renewable Energy Company
Glenmark Pharmaceuticals Limited Appoints Shweta Munjal as Chief Communications & CSR Officer
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action GLENMARK
  4. Actualités Glenmark Pharmaceuticals Limited
  5. Autres langues